Clinical Trial Update: A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating camrelizumab plus apatinib and oxaliplatin for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hepatocellular Carcinoma Resectable | Phase 2 | Status: UNKNOWN